These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34572883)

  • 1. The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Van Berckelaer C; Vermeiren I; Vercauteren L; Rypens C; Oner G; Trinh XB; Tjalma WAA; Broeckx G; Charafe-Jauffret E; Van Laere S; Bertucci F; Colpaert C; van Dam PA
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer.
    Van Berckelaer C; Van Geyt M; Linders S; Rypens C; Trinh XB; Tjalma WAA; Van Laere S; Colpaert C; Dirix L; van Dam PA
    Breast; 2020 Oct; 53():212-220. PubMed ID: 32890963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
    Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.
    De Schepper M; Nguyen HL; Richard F; Rosias L; Lerebours F; Vion R; Clatot F; Berghian A; Maetens M; Leduc S; Isnaldi E; Molinelli C; Lambertini M; Grillo F; Zoppoli G; Dirix L; Punie K; Wildiers H; Smeets A; Nevelsteen I; Neven P; Vincent-Salomon A; Larsimont D; Duhem C; Viens P; Bertucci F; Biganzoli E; Vermeulen P; Floris G; Desmedt C
    Cancer Res Commun; 2024 Jan; 4(1):186-199. PubMed ID: 38147006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy.
    Li Z; Li S; Ying X; Zhang L; Shan F; Jia Y; Ji J
    Gastric Cancer; 2020 May; 23(3):540-549. PubMed ID: 32072387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.
    Lusho S; Durando X; Mouret-Reynier MA; Kossai M; Lacrampe N; Molnar I; Penault-Llorca F; Radosevic-Robin N; Abrial C
    Front Oncol; 2021; 11():678315. PubMed ID: 34367964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.
    Abuhadra N; Sun R; Litton JK; Rauch GM; Yam C; Chang JT; Seth S; Bassett R; Lim B; Thompson AM; Mittendorf E; Adrada BE; Damodaran S; White J; Ravenberg E; Candelaria R; Arun B; Ueno NT; Santiago L; Saleem S; Abouharb S; Murthy RK; Ibrahim N; Sahin AA; Valero V; Symmans WF; Tripathy D; Moulder S; Huo L
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis.
    Qi X; Chen J; Wei S; Ni J; Song L; Jin C; Yang L; Zhang X
    BMJ Open; 2023 Nov; 13(11):e074874. PubMed ID: 37996220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions.
    Jaime Dos Santos B; Balabram D; Mara Reis Gomes V; Costa Café de Castro C; Henrique Costa Diniz P; Araújo Buzelin M; Buzelin Nunes C
    Cancer Res Treat; 2024 Jan; 56(1):178-190. PubMed ID: 37536712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    O'Loughlin M; Andreu X; Bianchi S; Chemielik E; Cordoba A; Cserni G; Figueiredo P; Floris G; Foschini MP; Heikkilä P; Kulka J; Liepniece-Karele I; Regitnig P; Reiner A; Ryska A; Sapino A; Shalaby A; Stovgaard ES; Quinn C; Walsh EM; Zolota V; Glynn SA; Callagy G
    Breast Cancer Res Treat; 2018 Aug; 171(1):1-9. PubMed ID: 29774470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.
    Marín Hernández C; Piñero Madrona A; Gil Vázquez PJ; Galindo Fernández PJ; Ruiz Merino G; Alonso Romero JL; Parrilla Paricio P
    Clin Transl Oncol; 2018 Apr; 20(4):476-483. PubMed ID: 28785911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
    Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ
    Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocytes and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Dong X; Liu C; Yuan J; Wang S; Ding N; Li Y; Wu Y; Xiao Z
    Breast Care (Basel); 2021 Aug; 16(4):328-334. PubMed ID: 34602938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.
    Zhang R; Hu C; Zhang J; Zhang Y; Yuan L; Yu P; Wang Y; Bao Z; Cao M; Ruan R; Cheng X; Xu Z
    BMC Cancer; 2023 Jan; 23(1):5. PubMed ID: 36597055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer.
    Ilgun AS; Aktepe F; Gonullu O; Kapucuoglu N; Yararbas K; Alco G; Ozturk A; Elbuken Celebi F; Erdogan Z; Ordu C; Unal C; Duymaz T; Soybir G; Yavuz E; Tuzlali S; Ozmen V
    Future Oncol; 2022 Sep; 18(29):3289-3298. PubMed ID: 36017739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.